Pimozide Tablet Market Report 2026

The pimozide tablet market size has grown strongly in recent years. It will grow from $1.84 billion in 2025 to $2.02 billion in 2026 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to limited treatment options for tourette’s syndrome, rising prevalence of chronic schizophrenia, increasing hospital and clinic infrastructure, growing awareness of antipsychotic therapies, reliance on traditional offline pharmacies.

The pimozide tablet market size is expected to see strong growth in the next few years. It will grow to $2.91 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to development of low-dose and unit-dose pimozide tablets, expansion of online pharmacy platforms, rising home healthcare adoption, increasing government mental health initiatives, integration of digital adherence monitoring tools. Major trends in the forecast period include increasing awareness of tourette’s syndrome and chronic schizophrenia, rising preference for oral antipsychotic medications, growth in home-based mental health care and therapy, expansion of online pharmaceutical distribution channels, development of personalized dosing and packaging options.

The growing prevalence of psychiatric disorders is anticipated to drive the expansion of the pimozide tablet market in the coming years. Psychiatric disorders are mental health conditions marked by significant disruptions in thinking, emotions, or behavior, often resulting in distress or reduced functioning. The increase in these disorders is largely driven by higher stress levels, evolving societal norms, improved awareness and diagnostic practices, and genetic factors. Pimozide tablets are used in the treatment of psychiatric disorders to control symptoms such as delusions and tics by blocking dopamine receptors, which helps reduce abnormal brain activity. For example, in August 2025, according to the Substance Abuse and Mental Health Services Administration (SAMHSA), a US-based federal agency, 23.4% of adults aged 18 and above, or about 61.5 million people, experienced any mental illness (AMI), while approximately 5.6% reported a serious mental illness (SMI). In comparison, 22.8% (58.7 million people) and 5.7% (14.6 million people) of adults reported AMI and SMI, respectively, in 2023. As a result, the increasing prevalence of psychiatric disorders is contributing to the growth of the pimozide tablet market.

Rising investment in pharmaceutical manufacturing is also expected to support the growth of the pimozide tablet market in the future. Pharmaceutical manufacturing involves the production of medicines through the formulation, processing, and packaging of chemical or biological substances in compliance with strict quality standards to ensure safety and effectiveness for patients. Growth in pharmaceutical manufacturing is driven by the increasing demand for affordable generic medicines, encouraging companies to scale up production to address expanding healthcare needs. Pimozide tablets contribute to pharmaceutical manufacturing by offering a commercially viable central nervous system medication that stimulates production, formulation, and distribution activities across the industry. For instance, in June 2025, according to Les Entreprises du Médicament (Leem), a France-based professional organization representing pharmaceutical companies, manufacturing-related investment in France rose by 38% in 2024 compared with 2023. Therefore, rising investment in pharmaceutical manufacturing is fueling the growth of the pimozide tablet market.

The increase in healthcare expenditure is further expected to drive the growth of the pimozide tablet market. Healthcare spending continues to rise due to factors such as the growing cost of advanced medical technologies, aging populations, and the increasing burden of chronic diseases. Higher healthcare expenditure supports demand for pimozide tablets by improving access to mental health services and expanding insurance coverage for psychiatric medications. For example, in May 2024, according to the Office for National Statistics, a UK-based government department, healthcare expenditure in the UK increased from £277 ($319.91) billion in 2022 to £292 ($337.23) billion in 2023, reflecting a year-on-year rise in nominal terms. Consequently, the increase in healthcare expenditure is contributing to the growth of the pimozide tablet market.

Major companies operating in the pimozide tablet market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Novartis AG, Bristol-Myers Squibb, GlaxoSmithKline plc, C.H. Boehringer Sohn AG & Co. KG, Teva Pharmaceutical Industries Ltd., Hetero Drugs, Sun Pharmaceutical Industries Ltd., Jazz Pharmaceuticals, Aurobindo Pharma, Cipla Limited, Apotex Inc., H. Lundbeck A/S, Dr. Reddy's Laboratories, Hikma Pharmaceuticals, Amneal Pharmaceuticals, Endo International, Lupin Limited, Zydus Cadila, Alkem Laboratories, Torrent Pharmaceuticals, Glenmark Pharmaceuticals, Mallinckrodt Pharmaceuticals, Jubilant Life Sciences, Alembic Pharmaceuticals, Wockhardt, AA Pharma, Taj Pharmaceuticals.

North America was the largest region in the pimozide tablet market in 2025. The regions covered in the pimozide tablet market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pimozide tablet market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the pimozide tablet market by increasing costs of imported active pharmaceutical ingredients and packaging materials. Segments such as 1 mg, 2 mg, and 4 mg tablets, particularly those sold through online and offline channels in North America and Europe, are most affected. The resulting increase in production and distribution costs has slowed market growth. However, tariffs have encouraged local manufacturing, innovative packaging solutions, and cost-optimized production strategies that may improve long-term market resilience.

The pimozide tablet market research report is one of a series of new reports that provides pimozide tablet market statistics, including pimozide tablet industry global market size, regional shares, competitors with a pimozide tablet market share, detailed pimozide tablet market segments, market trends and opportunities, and any further data you may need to thrive in the pimozide tablet industry. This pimozide tablet market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pimozide tablets are antipsychotic drugs mainly prescribed for the treatment of Tourette’s syndrome and chronic psychotic disorders. They act by blocking dopamine receptors in the brain, which helps alleviate symptoms such as motor and vocal tics as well as hallucinations. These tablets are generally recommended when other treatment options have proven ineffective.

The primary types of pimozide tablets include 1 milligram, 2 milligrams, and 4 milligrams strengths. Pimozide 1 mg tablets contain the active ingredient pimozide along with inactive components such as calcium stearate, microcrystalline cellulose, lactose anhydrous, and corn starch. These tablets are distributed through both online and offline channels, with applications covering Tourette’s syndrome and chronic schizophrenia. They are used by a variety of end users, including hospitals, clinics, and for home-based treatment.

The pimozide tablet market consists of sales of orap, orap forte, and opiran. The market value includes the value of related goods sold by the service provider or included within the service offering. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.